|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||302.02 - 310.56|
|52-week range||261.27 - 387.40|
|Beta (5Y monthly)||1.27|
|PE ratio (TTM)||92.95|
|Earnings date||26 Jan 2022 - 31 Jan 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||379.80|
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.
DANVERS, Mass., January 14, 2022--Abiomed announces that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022.